Related Experiment Video
Updated: May 24, 2026
06:00
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
Published on: December 30, 2025
[Antibiotic prophylaxis in liver cirrhosis]
S Restellini1, M Nendaz, I Morard
1Service de médecine interne générale, Département de médecine interne, réhabilitation et gériatrie, HUG, 1211 Genève 14. Sophie.Restellini@hcuge.ch
Revue Medicale Suisse
|February 28, 2012
Summary
Antibiotic prophylaxis (ATP) can prevent spontaneous bacterial peritonitis (SBP) recurrence in cirrhosis patients. ATP improves survival in patients with low ascites protein, prior SBP, or gastrointestinal bleeding, reducing infection risks.
Area of Science:
- Hepatology
- Infectious Diseases
- Internal Medicine
Context:
- Cirrhosis patients frequently experience severe bacterial infections.
- Spontaneous bacterial peritonitis (SBP) is the most common infection in cirrhosis.
- SBP recurrence rates exceed 70% within one year, with 30-50% hospital mortality.
Purpose:
- To review the indications for antibiotic prophylaxis (ATP) in patients with cirrhosis.
- To highlight the role of ATP in preventing SBP and improving survival.
Summary:
- Key risk factors for SBP include low ascitic fluid protein, a history of SBP, and gastrointestinal bleeding.
- Antibiotic prophylaxis is indicated in these high-risk scenarios.
- Recognized indications for ATP significantly improve patient survival.
Impact:
- ATP represents a crucial strategy for managing bacterial infections in cirrhosis.
- Implementing ATP guidelines can reduce SBP recurrence and associated mortality.
- Improved survival rates are achievable through targeted antibiotic prophylaxis.
Related Concept Videos
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: